Effect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients

Carey, D. G., Cowin, G. J., Galloway, G. J., Jones, N. P., Richards, J. C., Bisivas, N. and Doddrell, D. M. (2002) Effect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients. Obesity Research, 10 10: 1008-1015. doi:10.1038/oby.2002.137


Author Carey, D. G.
Cowin, G. J.
Galloway, G. J.
Jones, N. P.
Richards, J. C.
Bisivas, N.
Doddrell, D. M.
Title Effect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients
Journal name Obesity Research   Check publisher's open access policy
ISSN 1071-7323
Publication date 2002-01-01
Sub-type Article (original research)
DOI 10.1038/oby.2002.137
Volume 10
Issue 10
Start page 1008
End page 1015
Total pages 8
Editor Corkey, B. E.
Place of publication Boston, USA
Publisher The North American Association for the Study of Obesity
Collection year 2002
Language eng
Subject C1
321004 Endocrinology
730105 Endocrine organs and diseases (incl. diabetes)
Abstract Objective: To investigate the effects of rosiglitazone (RSG) on insulin sensitivity and regional adiposity (including intrahepatic fat) in patients with type 2 diabetes. Research Methods and Procedures: We examined the effect of RSG (8 mg/day, 2 divided doses) compared with placebo on insulin sensitivity and body composition in 33 type 2 diabetic patients. Measurements of insulin sensitivity (euglycemic hyperinsulinemic clamp), body fat (abdominal magnetic resonance imaging and DXA), and liver fat (magnetic resonance spectroscopy) were taken at baseline and repeated after 16 weeks of treatment. Results: There was a significant improvement in glycemic control (glycosylated hemoglobin -0.7 +/- 0.7%, p less than or equal to 0.05) and an 86% increase in insulin sensitivity in the RSG group (glucose-disposal rate change from baseline: 17.5 +/- 14.5 mumol glucose/min/kg free fat mass, P < 0.05), but no significant change in the placebo group compared with baseline. Total body weight and fat mass increased (p &LE; 0.05) with RSG (2.1 +/- 2.0 kg and 1.4 +/- 1.6 kg, respectively) with 95% of the increase in adiposity occurring in nonabdominal regions. In the abdominal region, RSG increased subcutaneous fat area by 8% (25.0 +/- 28.7 cm(2), p = 0.02), did not alter intra-abdominal fat area, and reduced intrahepatic fat levels by 45% (-6.7 +/- 9.7%, concentration relative to water). Discussion: Our data indicate that RSG greatly improves insulin sensitivity in patients with type 2 diabetes and is associated with an increase in adiposity in subcutaneous but not visceral body regions.
Keyword Endocrinology & Metabolism
Nutrition & Dietetics
Rosiglitazone
Insulin Sensitivity
Type 2 Diabetes
Body-fat Distribution
Adipose Tissue
Adipose-tissue Distribution
Fat Distribution
Liver Fat
Lipid Availability
Abdominal Fat
Obese Women
Resistance
Niddm
Rat
Troglitazone
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
Centre for Advanced Imaging Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 161 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 04:38:20 EST